πŸ‡ΊπŸ‡Έ FDA

Intelligence Platform

Patents

Browse 416 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 12290505

Tissue factor-targeted antibody-drug conjugate

SHANGHAI MIRACOGEN INC. Β· Granted Tue May 06 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 01 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12291571

Methods for reducing eosinophilic infiltration by administering an anti-interleukin-4 rece

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue May 06 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 01 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12286479

Treatment with anti-Ξ±4Ξ²7 antibody

Takeda Pharmaceutical Company Limited Β· Granted Tue Apr 29 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 24 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12280124

Antibody-drug conjugates comprising GLP1 peptidomimetics and uses thereof

REGENERON PHARMACEUTICALS, INC. Β· Granted Tue Apr 22 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 17 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12269886

Tetravalent bispecific antibody against PD-1 and PD-L1

SUNSHINE GUOJIAN PHARMACEUTICAL (SHANGHAI) CO., LTD. Β· Granted Tue Apr 08 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 03 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12263225

Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an o

Dyne Therapeutics, Inc. Β· Granted Tue Apr 01 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12246064

Method of treating Crohn's disease by administering a triple combination therapy of anti-i

Takeda Pharmaceutical Company Limited Β· Granted Tue Mar 11 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 06 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12240914

Antibody against factor XIa in activated form of coagulant factor XI, preparation method t

MAB-LEGEND BIOTECH CO., LTD. Β· Granted Tue Mar 04 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12234294

Pharmaceutical composition of a humanized anti-CD40 antibody

Kiniksa Pharmaceuticals, GmbH Β· Granted Tue Feb 25 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 20 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12234295

Chimeric transmembrane protein comprising antibody dimerization domains and a type I cytok

AUTOLUS LIMITED Β· Granted Tue Feb 25 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 20 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12226490

Anti-ROR1 antibody conjugates, compositions comprising anti ROR1 antibody conjugates, and

Sutro Biopharma, Inc. Β· Granted Tue Feb 18 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 13 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12226524

Coated implants for long-term controlled release of antibody therapeutics

THE REGENTS OF THE UNIVERSITY OF MICHIGAN Β· Granted Tue Feb 18 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 13 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12221460

Antibody drug conjugates

Takeda Pharmaceutical Company Limited Β· Granted Tue Feb 11 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 06 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12188005

NK cells with an increased antibody-dependent cellular toxicity (ADCC) against tumors

The United States of America, as represented by the Secretary, Department of Health and Human Services Β· Granted Tue Jan 07 2025 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 02 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12180277

LILRB4-binding antibody and methods of use thereof

The Board of Regents of the University of Texas System Β· Granted Tue Dec 31 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 26 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12173084

Phosphorylated dicer antibody and methods of use thereof

The Board of Regents of the University of Texas System Β· Granted Tue Dec 24 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12173078

Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide

Dyne Therapeutics, Inc. Β· Granted Tue Dec 24 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12173079

Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an o

Dyne Therapeutics, Inc. Β· Granted Tue Dec 24 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12168054

Method of treating cancer using a combination of entinostat and an anti-CSF-1R antibody

Syndax Pharmaceuticals, Inc. Β· Granted Tue Dec 17 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 12 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12161717

CD38 modulating antibody agents

BLACK BELT THERAPEUTICS LIMITED Β· Granted Tue Dec 10 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 05 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12162949

CD38 antibody

BLACK BELT THERAPEUTICS LIMITED Β· Granted Tue Dec 10 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 05 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12162937

Methods of treating an inflammatory disorder by administering an antibody which binds to a

The Board of Regents of the University of Texas System Β· Granted Tue Dec 10 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 05 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12156870

Antibody drug conjugates comprising sting agonists

Mersana Therapeutics, Inc. Β· Granted Tue Dec 03 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 28 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 12144869

Anti-ROR1 antibody conjugates, compositions comprising anti ROR1 antibody conjugates, and

Sutro Biopharma, Inc. Β· Granted Tue Nov 19 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 14 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted